{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:44:30Z","timestamp":1776800670587,"version":"3.51.2"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.intimp.2026.116515","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:52:47Z","timestamp":1773831167000},"page":"116515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stress\u2013immune\u2013Repigmentation niche in vitiligo: Mechanistic integration and therapeutic implications"],"prefix":"10.1016","volume":"177","author":[{"given":"Guangman","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang E.","family":"Chui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haonan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menghan","family":"Di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116515_bb0005","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1016\/S2468-2667(24)00026-4","article-title":"Estimating the burden of vitiligo: a systematic review and modelling study","volume":"9","author":"Akl","year":"2024","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.intimp.2026.116515_bb0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054910","article-title":"Vitiligo, from pathogenesis to therapeutic advances: state of the art","volume":"24","author":"Diotallevi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116515_bb0020","article-title":"Vitiligo: a call for paradigm shift toward comprehensive patient care","volume":"12","author":"Sigova","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.intimp.2026.116515_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0030","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250281","article-title":"The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: pathological mechanism and treatment","volume":"54","author":"Liu","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0035","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s00403-021-02228-9","article-title":"Systemic CXCL10 is a predictive biomarker of vitiligo lesional skin infiltration, PUVA, NB-UVB and corticosteroid treatment response and outcome","volume":"314","author":"El-Domyati","year":"2022","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2026.116515_bb0040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.5114\/ada.2024.138672","article-title":"Serum cytokine profiles predict response to systemic glucocorticoid in active vitiligo","volume":"41","author":"Wang","year":"2024","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.intimp.2026.116515_bb0045","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/cells12060936","article-title":"The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications","volume":"12","author":"Chang","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2026.116515_bb0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/cei\/uxab002","article-title":"Patho-immunological mechanisms of vitiligo: the role of the innate and adaptive immunities and environmental stress factors","volume":"207","author":"Faraj","year":"2022","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0055","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40291-023-00672-z","article-title":"Oxidative stress and potential antioxidant therapies in vitiligo: a narrative review","volume":"27","author":"Bia\u0142czyk","year":"2023","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.intimp.2026.116515_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613056","article-title":"Targeting innate immunity to combat cutaneous stress: the vitiligo perspective","volume":"12","author":"Boniface","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/biom13010020","article-title":"NRF2 in the epidermal pigmentary system","volume":"13","author":"Ogawa","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.intimp.2026.116515_bb0070","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.jid.2019.03.1165","article-title":"Molecular hydrogen protects human melanocytes from oxidative stress by activating Nrf2 signaling","volume":"140","author":"Fang","year":"2020","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0075","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1038\/s41598-025-86061-4","article-title":"Bioinformatic analysis of ferroptosis related biomarkers and potential therapeutic targets in vitiligo","volume":"15","author":"Liu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2026.116515_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/pcmr.13032","article-title":"Altered expression of ferroptosis markers and iron metabolism reveals a potential role of ferroptosis in vitiligo","volume":"35","author":"Wu","year":"2022","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.intimp.2026.116515_bb0085","article-title":"SIRT7 facilitates ferroptosis resistance of melanocytes via activating the SMAD3-ATF3-GPX4 signaling pathway in vitiligo","author":"Wu","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.intimp.2026.116515_bb0090","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/15548627.2024.2319901","article-title":"International consensus guidelines for the definition, detection, and interpretation of autophagy-dependent ferroptosis","volume":"20","author":"Chen","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.intimp.2026.116515_bb0095","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12864-024-10147-y","article-title":"Identification and validation of RNA-binding protein SLC3A2 regulates melanocyte ferroptosis in vitiligo by integrated analysis of single-cell and bulk RNA-sequencing","volume":"25","author":"Zhang","year":"2024","journal-title":"BMC Genomics"},{"key":"10.1016\/j.intimp.2026.116515_bb0100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","article-title":"Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy","volume":"12","author":"Koppula","year":"2021","journal-title":"Protein Cell"},{"key":"10.1016\/j.intimp.2026.116515_bb0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","article-title":"Ferroptosis: mechanisms, biology and role in disease","volume":"22","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2026.116515_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120868","article-title":"Focus on ferroptosis regulation: exploring novel mechanisms and applications of ferroptosis regulator","volume":"307","author":"Ma","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2026.116515_bb0115","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/13510002.2022.2123864","article-title":"Damage-associated molecular patterns in vitiligo: igniter fuse from oxidative stress to melanocyte loss","volume":"27","author":"Wang","year":"2022","journal-title":"Redox Rep."},{"key":"10.1016\/j.intimp.2026.116515_bb0120","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.jid.2024.01.007","article-title":"Membranal expression of calreticulin induced by unfolded protein response in melanocytes: a mechanism underlying oxidative stress-induced autoimmunity in vitiligo","volume":"144","author":"Song","year":"2024","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0125","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.2147\/CCID.S381432","article-title":"Role of HMGB1 in vitiligo: current perceptions and future perspectives","volume":"15","author":"Wei","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0130","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.jid.2017.08.038","article-title":"Vitiligo skin is imprinted with resident memory CD8 T cells expressing CXCR3","volume":"138","author":"Boniface","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0135","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/exd.13879","article-title":"Vitiligo as a skin memory disease: the need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cells","volume":"28","author":"Boniface","year":"2019","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102868","article-title":"Emerging role of tissue resident memory T cells in vitiligo: from pathogenesis to therapeutics","volume":"20","author":"Shah","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2026.116515_bb0145","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.4049\/jimmunol.2100277","article-title":"IL-15 trans-presentation is an autonomous, antigen-independent process","volume":"207","author":"Kenesei","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13164919","article-title":"Role of cytokines and chemokines in vitiligo and their therapeutic implications","volume":"13","author":"K\u0105dziela","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.intimp.2026.116515_bb0155","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1111\/febs.16272","article-title":"Interferon-\u03b3 induces retinal pigment epithelial cell ferroptosis by a JAK1-2\/STAT1\/SLC7A11 signaling pathway in age-related macular degeneration","volume":"289","author":"Wei","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2026.116515_bb0160","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/JLB.3MA1220-815RRR","article-title":"IFN\u03b3-mediated repression of system xc- drives vulnerability to induced ferroptosis in hepatocellular carcinoma cells","volume":"110","author":"Kong","year":"2021","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2026.116515_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06993-z","article-title":"The involvement of the Stat1\/Nrf2 pathway in exacerbating crizotinib-induced liver injury: implications for ferroptosis","volume":"15","author":"Guo","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.intimp.2026.116515_bb0170","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116515_bb0175","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1093\/bjd\/ljaf485","article-title":"Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the topical Ruxolitinib evaluation in vitiligo (TRuE-V) long-term extension phase III study","volume":"194","author":"Harris","year":"2026","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0180","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s12016-025-09048-z","article-title":"Epigenetic modifications in vitiligo","volume":"68","author":"Huang","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2026.116515_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102580","article-title":"Epigenetic regulation in vitiligo: mechanisms, challenges, and therapeutic opportunities","volume":"95","author":"Wu","year":"2025","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109574","article-title":"Overexpressed perforin contributes to the melanocyte destruction via epigenetic regulation in patients with vitiligo","volume":"114","author":"Deng","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2026.116515_bb0195","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.2147\/CCID.S462280","article-title":"SIRT7 inhibits melanin synthesis of PIG1 and PIG3V by suppressing the succinylation of EZR","volume":"17","author":"Ma","year":"2024","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1016\/j.intimp.2026.116515_bb0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00403-025-04113-1","article-title":"Non-coding RNAs (miRNAs - circRNAs - lncRNAs) and genes interact with the regulation of vitiligo","volume":"317","author":"AbdElneam","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2026.116515_bb0205","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5021\/ad.2020.32.6.441","article-title":"The role of microRNAs in vitiligo: regulators and therapeutic targets","volume":"32","author":"Li","year":"2020","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0210","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12016-021-08868-z","article-title":"Clinical features, immunopathogenesis, and therapeutic strategies in vitiligo","volume":"61","author":"Wang","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.intimp.2026.116515_bb0215","article-title":"The role of aryl hydrocarbon receptor in vitiligo: a review","volume":"15","author":"Li","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0220","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jid.2025.07.027","article-title":"Downregulated aryl hydrocarbon receptor expression is linked with increased IFN-\u03b3 production and impaired immune checkpoint upregulation in vitiligo","volume":"146","author":"Belpaire","year":"2026","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0225","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185785","article-title":"Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity","volume":"135","author":"Ezzedine","year":"2025","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2026.116515_bb0230","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.tim.2023.01.009","article-title":"The epidermal lipid barrier in microbiome-skin interaction","volume":"31","author":"Kengmo Tchoupa","year":"2023","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.intimp.2026.116515_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.652191","article-title":"Resident memory T cells in autoimmune skin diseases","volume":"12","author":"Ryan","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1639732","article-title":"Targeting the IL-15\/CD122 signaling pathway: reversing TRM cell-mediated immune memory in vitiligo","volume":"16","author":"Su","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0245","doi-asserted-by":"crossref","DOI":"10.1111\/exd.14982","article-title":"Compromised melanocyte survival due to decreased suppression of CD4+ & CD8+ resident memory T cells by impaired TRM-regulatory T cells in generalized vitiligo patients","volume":"33","author":"Shah","year":"2024","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0250","doi-asserted-by":"crossref","DOI":"10.1093\/oxfimm\/iqae006","article-title":"The emerging role of effector functions exerted by tissue-resident memory T cells","volume":"5","author":"Iijima","year":"2024","journal-title":"Oxf Open Immunol"},{"key":"10.1016\/j.intimp.2026.116515_bb0255","article-title":"Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle","volume":"11","author":"Zhou","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.intimp.2026.116515_bb0260","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1111\/jdv.19022","article-title":"The possible role of Wnt\/\u03b2-catenin signalling in vitiligo treatment","volume":"37","author":"Lin","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2026.116515_bb0265","doi-asserted-by":"crossref","first-page":"762","DOI":"10.5114\/ada.2021.110266","article-title":"Assessment of stem cell factor expression and its c-KIT receptor in patients with vitiligo","volume":"39","author":"Wilamowska-Kokoszko","year":"2022","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.intimp.2026.116515_bb0270","article-title":"Melanocyte-keratinocyte cross-talk in vitiligo","volume":"10","author":"Touni","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.intimp.2026.116515_bb0275","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.gendis.2020.06.003","article-title":"SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the Wnt\/\u03b2-catenin signaling","volume":"8","author":"Zou","year":"2021","journal-title":"Genes Dis"},{"key":"10.1016\/j.intimp.2026.116515_bb0280","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jaad.2025.06.006","article-title":"Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: a randomized controlled trial","volume":"93","author":"Dev","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0285","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00403-025-04151-9","article-title":"A retrospective analysis of the efficacy and safety of oral tofacitinib in active vitiligo treatment","volume":"317","author":"Hu","year":"2025","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2026.116515_bb0290","doi-asserted-by":"crossref","DOI":"10.1177\/15593258221105370","article-title":"Baricitinib is effective in treating progressing vitiligo in vivo and in vitro","volume":"20","author":"Dong","year":"2022","journal-title":"Dose Response"},{"key":"10.1016\/j.intimp.2026.116515_bb0295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1001\/jamadermatol.2024.5737","article-title":"Combination of baricitinib and phototherapy in adults with active vitiligo: a randomized clinical trial","volume":"161","author":"Seneschal","year":"2025","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0300","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s40265-025-02246-1","article-title":"JAK inhibitors for the treatment of vitiligo: current evidence and emerging therapeutic potential","volume":"85","author":"Ferreira","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2026.116515_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102655","article-title":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"73","author":"Passeron","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.intimp.2026.116515_bb0310","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2200873","article-title":"Concurrent vitiligo and atopic dermatitis successfully treated with upadacitinib: a case report","volume":"34","author":"Pan","year":"2023","journal-title":"J. Dermatolog. Treat."},{"key":"10.1016\/j.intimp.2026.116515_bb0315","author":"AbbVie"},{"key":"10.1016\/j.intimp.2026.116515_bb0320","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2026.116515_bb0325","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0330","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40257-022-00752-6","article-title":"Vitiligo treatments: review of current therapeutic modalities and JAK inhibitors","volume":"24","author":"Cunningham","year":"2023","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0335","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/ajd.14353","article-title":"A narrative review of the literature: the role of biologics and JAK inhibitors in vitiligo","volume":"65","author":"Russell","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0340","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000510831","article-title":"Vitiligo with progressive repigmentation during secukinumab treatment in a patient with psoriatic arthritis: a case report","volume":"13","author":"Giordano","year":"2021","journal-title":"Case Rep. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/life15050684","article-title":"Comprehensive overview of cytokine interplay in vitiligo: a decade of meta-analyses systematically reviewed","volume":"15","author":"Paganelli","year":"2025","journal-title":"Life"},{"key":"10.1016\/j.intimp.2026.116515_bb0350","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/pcmr.12789","article-title":"IL-17A is not a treatment target in progressive vitiligo","volume":"32","author":"Speeckaert","year":"2019","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.intimp.2026.116515_bb0355","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/bjd.14057","article-title":"Tumour necrosis factor-\u03b1 antagonists as therapies for vitiligo","volume":"173","author":"Kemp","year":"2015","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0360","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jid.2017.11.012","article-title":"Increased risk of vitiligo following anti-tumor necrosis factor therapy: a 10-year population-based cohort study","volume":"138","author":"Bae","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0365","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e11","article-title":"IL-15 in T-cell responses and immunopathogenesis","volume":"24","author":"Lee","year":"2024","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2026.116515_bb0370","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116515_bb0375","doi-asserted-by":"crossref","first-page":"9749","DOI":"10.3390\/ijms24119749","article-title":"Etiopathogenesis and emerging methods for treatment of vitiligo","volume":"24","author":"Iwanowski","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.intimp.2026.116515_bb0380","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/14728222.2023.2193329","article-title":"Treatment update for vitiligo based on autoimmune inhibition and melanocyte protection","volume":"27","author":"Xie","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.intimp.2026.116515_bb0385","doi-asserted-by":"crossref","first-page":"174ra28","DOI":"10.1126\/scitranslmed.3005127","article-title":"Mutant HSP70 reverses autoimmune depigmentation in vitiligo","volume":"5","author":"Mosenson","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116515_bb0390","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jid.2018.06.186","article-title":"HSP70iQ435A-encoding DNA repigments vitiligo lesions in Sinclair swine","volume":"138","author":"Henning","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0395","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41580-024-00823-y","article-title":"Mechanistic insights into Wnt-\u03b2-catenin pathway activation and signal transduction","volume":"26","author":"Maurice","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.intimp.2026.116515_bb0400","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1038\/jid.2015.335","article-title":"Transcriptional analysis of vitiligo skin reveals the alteration of Wnt pathway: a promising target for repigmenting vitiligo patients","volume":"135","author":"Regazzetti","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0405","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1111\/jocd.16274","article-title":"Evaluation of efficacy and safety of vitiligo treatment with micro-needling combined with N-acetylcysteine and micro-needling alone: a double-blinded randomized controlled clinical trial","volume":"23","author":"Atefi","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0410","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/scd.2021.0276","article-title":"Micro-injury induces hair regeneration and vitiligo repigmentation through Wnt\/\u03b2-catenin pathway","volume":"31","author":"Han","year":"2022","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.intimp.2026.116515_bb0415","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jdcr.2023.06.051","article-title":"Vitiligo responds to topical aryl hydrocarbon receptor agonist tapinarof (WBI-1001)","volume":"39","author":"Liu","year":"2023","journal-title":"JAAD Case Rep."},{"key":"10.1016\/j.intimp.2026.116515_bb0420","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3892\/etm.2020.9589","article-title":"Reciprocal regulation of interleukin-17A and interleukin-22 secretion through aryl hydrocarbon receptor activation in CD4+ T cells of patients with vitiligo","volume":"21","author":"Liu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.intimp.2026.116515_bb0425","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bjd.20596","article-title":"British Association of Dermatologists guidelines for the management of people with vitiligo 2021","volume":"186","author":"Eleftheriadou","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0430","doi-asserted-by":"crossref","DOI":"10.1111\/srt.13642","article-title":"A systematic review of case series and clinical trials investigating systemic oral or injectable therapies for the treatment of vitiligo","volume":"30","author":"Jafarzadeh","year":"2024","journal-title":"Skin Res. Technol."},{"key":"10.1016\/j.intimp.2026.116515_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101766","article-title":"Vitiligo: an immune disease and its emerging mesenchymal stem cell therapy paradigm","volume":"76","author":"Zhang","year":"2023","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.intimp.2026.116515_bb0440","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/bjd\/ljac074","article-title":"Has the core outcome (domain) set for vitiligo been implemented? An updated systematic review on outcomes and outcome measures in vitiligo randomized clinical trials","volume":"188","author":"Eleftheriadou","year":"2023","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.intimp.2026.116515_bb0445","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1007\/s00403-023-02608-3","article-title":"Implementation of the vitiligo area scoring index in clinical studies of patients with vitiligo: a scoping review","volume":"315","author":"Ceresnie","year":"2023","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.intimp.2026.116515_bb0450","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force-part 2: specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2026.116515_bb0455","first-page":"365","article-title":"S1 guideline: diagnosis and therapy of vitiligo","volume":"20","author":"B\u00f6hm","year":"2022","journal-title":"J. Dtsch. Dermatol. Ges."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926003607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926003607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T18:45:02Z","timestamp":1776105902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926003607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":91,"alternative-id":["S1567576926003607"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116515","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stress\u2013immune\u2013Repigmentation niche in vitiligo: Mechanistic integration and therapeutic implications","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116515"}}